Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia

por Meyer, Jonathan M., Mao, Yongcai, Pikalov, Andrei, Cucchiaro, Josephine, Loebel, Antony
Publicado 2015

Efficacy and Safety of Lurasidone in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study

por Goldman, Robert, Loebel, Antony, Cucchiaro, Josephine, Deng, Ling, Findling, Robert L.
Publicado 2017

PM418. Efficacy of Lurasidone in Patients With Schizophrenia With Prominent Positive Symptoms: A Pooled Analysis of Short-Term Placebo-Controlled Studies

por Potkin, Steven G., Tocco, Michael, Mao, Yongcai, Cucchiaro, Josephine, Loebel, Antony
Publicado 2016

Long-term use of lurasidone in patients with bipolar disorder: safety and effectiveness over 2 years of treatment

por Pikalov, Andrei, Tsai, Joyce, Mao, Yongcai, Silva, Robert, Cucchiaro, Josephine, Loebel, Antony
Publicado 2017

F52. EFFICACY AND SAFETY OF LURASIDONE IN ADOLESCENTS WITH SCHIZOPHRENIA: INTERIM ANALYSIS OF A 24-MONTH, OPEN-LABEL EXTENSION STUDY

por Goldman, Robert, Tocco, Michael, Pikalov, Andrei, Cucchiaro, Josephine, Deng, Ling, Loebel, Antony
Publicado 2018

LURASIDONE IN THE LONG‐TERM TREATMENT OF PATIENTS WITH BIPOLAR DISORDER: A 24‐WEEK OPEN‐LABEL EXTENSION STUDY

por Ketter, Terence A., Sarma, Kaushik, Silva, Robert, Kroger, Hans, Cucchiaro, Josephine, Loebel, Antony
Publicado 2016

PM413. Metabolic Syndrome in Patients With Schizophrenia Receiving Long-Term Treatment With Lurasidone, Quetiapine XR, or Risperidone

por Newcomer, John W., Tocco, Michael, Pikalov, Andrei, Zheng, Hanzhe, Cucchiaro, Josephine, Loebel, Antony
Publicado 2016

T5. LURASIDONE AND RISK FOR METABOLIC SYNDROME IN PATIENTS WITH SCHIZOPHRENIA: A COMPREHENSIVE DATABASE ANALYSIS

por Tocco, Michael, Pikalov, Andrei, Hsu, Jay, Cucchiaro, Josephine, Newcomer, John W, Loebel, Antony
Publicado 2018

S73. EFFECT OF LURASIDONE ON COGNITION IN ADOLESCENTS WITH SCHIZOPHRENIA: INTERIM ANALYSIS OF A 2-YEAR OPEN-LABEL EXTENSION STUDY

por Harvey, Philip D, Goldman, Robert, Tocco, Michael, Deng, Ling, Cucchiaro, Josephine, Loebel, Antony
Publicado 2018

Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo-controlled studies

por Nasrallah, Henry A., Cucchiaro, Josephine B., Mao, Yongcai, Pikalov, Andrei A., Loebel, Antony D.
Publicado 2014

Treatment of early non-response in patients with schizophrenia: assessing the efficacy of antipsychotic dose escalation

por Loebel, Antony, Citrome, Leslie, Correll, Christoph U., Xu, Jane, Cucchiaro, Josephine, Kane, John M.
Publicado 2015

A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia

por Tandon, Rajiv, Cucchiaro, Josephine, Phillips, Debra, Hernandez, David, Mao, Yongcai, Pikalov, Andrei, Loebel, Antony
Publicado 2016

Daytime sleepiness associated with lurasidone and quetiapine XR: results from a randomized double-blind, placebo-controlled trial in patients with schizophrenia

por Loebel, Antony D., Siu, Cynthia O., Cucchiaro, Josephine B., Pikalov, Andrei A., Harvey, Philip D.
Publicado 2013

Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study

por Citrome, Leslie, Weiden, Peter J, McEvoy, Joseph P, Correll, Christoph U., Cucchiaro, Josephine, Hsu, Jay, Loebel, Antony
Publicado 2013